Building on robust evidence from pivotal phase II–III trials, sotatercept, a first-in-class agent targeting dysregulated activin/GDF signalling within the TGF-β superfamily, has expanded the therapeutic landscape beyond conventional vasodilator pathways and supports the concept of disease modification in PAH. Here, INHBE is linked to pulmonary arterial hypertension.